Venetoclax Plus Azacitidine
A Phase I/II Study of Venetoclax in Combination With Azacitidine in Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 58 patients (estimated)
- Sponsors
- MD Anderson Cancer Center
- Collaborators
- National Cancer Institute (NCI), Genentech
- Tags
- BCL-2 Inhibitor
- Trial Type
- Treatment
- Last Update
- 4 weeks ago
- SparkCures ID
- 1508
- NCT Identifier
- NCT04550442
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.